https://www.selleckchem.com/pr....oducts/Nafamostat-me
On one hand, IR820@ZIF-8 is modified with hyaluronic acid for realizing tumor-targeted photothermal therapy, accompanied with the release of tumor antigens. On the other hand, (R837+1 MT)@ZIF-8 is modified with mannan for achieving DCs-targeted immune amplification. The synergistic tumor cells-targeted treatment and DCs-targeted immunomodulation can efficiently overcome two major obstacles in immunotherapy inadequate activation of immune response and immune evasion, offering powerful platform against invasive malignancy and
Like
Comment
Share
